UCLA's JCCC is designated by the National Cancer Institute as a comprehensive treatment facility with a membership of 230 physicians and scientists. They have established an international reputation for developing new cancer therapies, including the breast cancer drug, Herceptin. The Resolver system will be used as a gene expression analysis framework to investigate potential new therapies.
"The Resolver system will be an important asset to our research because of its data management and analysis capabilities for gene expression profiling," said Dr. Richard Finn, M.D., Member of the JCCC Signal Transduction and Therapeutics Program Area.
“We are pleased and honored to provide the Resolver system to the prestigious Jonsson Comprehensive Cancer Center," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
"JCCC’s use of the Resolver system is in line with Rosetta Biosoftware’s mission to develop software solutions to empower research that improves the quality of human life,” Shevelenko added.